Correction: B and T lymphocyte attenuator inhibits LPSinduced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells(Proc Natl Acad Sci USA (2013)110(5121–5126) DOI :10.1073/pnas.1222093110);B and T lymphocyte attenuator inhibits LPS-induced endotoxic shock by suppressing Toll-like receptor 4 signaling in innate immune cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 13, 2013, Pages 5121-5126

  Kobayashi, Yoshihisa ^a   Iwata, Arifumi ^a   Suzuki, Kotaro ^a   Suto, Akira ^a   Kawashima, Saki ^a   Saito, Yukari ^a   Owada, Takayoshi ^a   Kobayashi, Midori ^a   Watanabe, Norihiko ^a,b   Nakajima, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Division of Rheumatology and Clinical Immunology   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; B AND T LYMPHOCYTE ATTENUATOR ANTIBODY; IMMUNOMODULATING AGENT; INTERLEUKIN 12P70; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN SH2; RECEPTOR; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; DISEASE PREDISPOSITION; ENDOSOME; FLOW CYTOMETRY; IMMUNOMODULATION; INNATE IMMUNITY; LIPID RAFT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

MUS;

EID: 84875507855     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1805035115     Document Type: Erratum

References (36)

1. Riedemann NC, Guo RF, Ward PA (2003) Novel strategies for the treatment of sepsis. Nat Med 9(5):517-524.
2. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG (2011) The pathogenesis of sepsis. Annu Rev Pathol 6:19-48.
3. Munford RS (2006) Severe sepsis and septic shock: The role of gram-negative bacteremia. Annu Rev Pathol 1:467-496.
4. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 11(5):373-384.
5. Karima R, Matsumoto S, Higashi H, Matsushima K (1999) The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 5(3):123-132.
6. Ulloa L, Tracey KJ (2005) The "cytokine profile": A code for sepsis. Trends Mol Med 11(2):56-63.
7. Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365(9453):63-78.
8. Feng Y, et al. (2011) MyD88 and Trif signaling play distinct roles in cardiac dysfunction and mortality during endotoxin shock and polymicrobial sepsis. Anesthesiology 115(3):555-567.
9. Watanabe N, et al. (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4(7):670-679.
10. Murphy TL, Murphy KM (2010) Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol 28:389-411.
11. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM (2003) Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 312(4):1236-1243.
12. Tao R, et al. (2005) Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol 175(9):5774-5782.
13. Steinberg MW, et al. (2008) A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med 205(6):1463-1476.
14. Iwata A, et al. (2010) Protective roles of B and T lymphocyte attenuator in NKT cellmediated experimental hepatitis. J Immunol 184(1):127-133.
15. Oya Y, et al. (2008) Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum 58(8):2498-2510.
16. Albring JC, et al. (2010) Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med 207(12): 2551-2559.
17. Nakagomi D, et al. (2013) Therapeutic potential of B and T lymphocyte attenuator expressed on CD8(+) T cells for contact hypersensitivity. J Invest Dermatol 133(3):702-711.
18. Sun Y, et al. (2009) B and T lymphocyte attenuator tempers early infection immunity. J Immunol 183(3):1946-1951.
19. Shubin NJ, et al. (2012) BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 92(3):593-603.
20. Adler G, et al. (2011) B and T lymphocyte attenuator restricts the protective immune response against experimental malaria. J Immunol 187(10):5310-5319.
21. Ozmen L, et al. (1994) Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. J Exp Med 180(3):907-915.
22. Hurchla MA, et al. (2005) B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol 174(6):3377-3385.
23. Cheung TC, et al. (2009) Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc Natl Acad Sci USA 106(15):6244-6249.
24. Lepenies B, et al. (2007) Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria. J Immunol 179(6):4093-4100.
25. An H, et al. (2006) SHP-2 phosphatase negatively regulates the TRIF adaptor proteindependent type I interferon and proinflammatory cytokine production. Immunity 25(6):919-928.
26. An H, et al. (2008) Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 9(5):542-550.
27. Ramachandran IR, et al. (2011) The phosphatase SRC homology region 2 domaincontaining phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol 186(7):3934-3945.
28. Xu S, et al. (2012) Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps-SHP-2 pathway. Nat Immunol 13(6):551-559.
29. Owada T, et al. (2010) Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells. J Leukoc Biol 87(3):425-432.
30. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K (2002) Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 115(Pt 12):2603-2611.
31. Shi L, et al. (2006) DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood 108(8):2678-2686.
32. Liang S, et al. (2008) Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc Natl Acad Sci USA 105(24):8357-8362.
33. Kanazawa N, Tashiro K, Miyachi Y (2004) Signaling and immune regulatory role of the dendritic cell immunoreceptor (DCIR) family lectins: DCIR, DCAR, dectin-2 and BDCA-2. Immunobiology 209(1-2):179-190.
34. Suzuki K, et al. (2002) Proteolytic processing of Stat6 signaling in mast cells as a negative regulatory mechanism. J Exp Med 196(1):27-38.
35. Maezawa Y, et al. (2006) Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J Immunol 176(2):1013-1018.
36. Zhang W, Trible RP, Samelson LE (1998) LAT palmitoylation: Its essential role in membranemicrodomain targeting and tyrosine phosphorylation during T cell activation. Immunity 9(2):239-246.